(firstQuint)Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies.

 This is a first-in-human, Phase 1, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of repeated intratumoral injections of mRNA 2416 in patients with advanced relapsed/refractory solid tumor malignancies or lymphoma.

 The study will include 2 dosing periods: a Dose Escalation Period followed by an Expansion Period at the MTD/RDE as determined by the Dose Escalation Period.

.

 Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies@highlight

This clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma